OpGen (NASDAQ:OPGN) Now Covered by Analysts at StockNews.com

StockNews.com started coverage on shares of OpGen (NASDAQ:OPGN) in a research note published on Friday. The brokerage issued a sell rating on the medical research company’s stock.

OpGen Trading Up 8.2 %

OpGen stock traded up $0.14 during mid-day trading on Friday, hitting $1.81. 4,560 shares of the company’s stock were exchanged, compared to its average volume of 64,278. OpGen has a 1-year low of $1.49 and a 1-year high of $9.90. The stock has a 50 day moving average of $1.89 and a two-hundred day moving average of $2.83.

OpGen (NASDAQ:OPGN) last posted its earnings results on Monday, August 19th. The medical research company reported ($1.18) EPS for the quarter. The business had revenue of $0.03 million for the quarter.

Hedge Funds Weigh In On OpGen

An institutional investor recently bought a new position in OpGen stock. Chase Investment Counsel Corp bought a new position in shares of OpGen, Inc. (NASDAQ:OPGN) during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 331,890 shares of the medical research company’s stock, valued at approximately $230,000. Chase Investment Counsel Corp owned about 2.63% of OpGen at the end of the most recent reporting period. Hedge funds and other institutional investors own 2.68% of the company’s stock.

OpGen Company Profile

OpGen, Inc, a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits.